Hormone Sensitive Prostate Cancer

• CLINICAL_TRIALS trial_result · 2026-04-27
  Clinical Trial Update: This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. [Phase 3]

  Phase 3 trial investigating whether combining Mevrometostat (PF-06821497) with enzalutamide improves outcomes versus enzalutamide alone in A…

• CLINICAL_TRIALS trial_result · 2024-03-25
  Clinical Trial Update: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) [Phase 3]

  Phase 3 trial update evaluating enzalutamide with leuprolide in nonmetastatic prostate cancer; results posted and study status is active not…

• CLINICAL_TRIALS trial_result · 2023-08-09
  Clinical Trial Update: Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC [Phase 3]

  Phase 3 trial comparing rezvilutamide with ADT and docetaxel versus rezvilutamide with ADT in metastatic hormone-sensitive prostate cancer i…

• CLINICAL_TRIALS trial_result · 2023-02-08
  Clinical Trial Update: APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer [Phase 2]

  Phase 2 trial update exploring apalutamide with stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer.

• CLINICAL_TRIALS trial_result · 2019-12-02
  Clinical Trial Update: Cardiovascular Events in GnRH Agonist vs. Antagonist [Phase 2]

  Phase 2 trial update comparing GnRH agonist vs antagonist with a focus on cardiovascular events in prostate cancer patients.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.